ArQule gains on tivantinib data in HCC

ArQule Inc. (NASDAQ:ARQL) gained $0.71 (12%) to $6.67 on Tuesday after oral tivantinib met the primary endpoint of significantly improving time to progression vs. placebo in a Phase II trial to treat ...